MA54503A - Arn codant pour une protéine - Google Patents

Arn codant pour une protéine

Info

Publication number
MA54503A
MA54503A MA054503A MA54503A MA54503A MA 54503 A MA54503 A MA 54503A MA 054503 A MA054503 A MA 054503A MA 54503 A MA54503 A MA 54503A MA 54503 A MA54503 A MA 54503A
Authority
MA
Morocco
Prior art keywords
protein
rna coding
rna
coding
Prior art date
Application number
MA054503A
Other languages
English (en)
Inventor
Friedrich Metzger
Hervé Schaffhauser
Justin Antony Selvaraj
Original Assignee
Versameb Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versameb Ag filed Critical Versameb Ag
Publication of MA54503A publication Critical patent/MA54503A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA054503A 2018-12-19 2019-12-18 Arn codant pour une protéine MA54503A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18214221 2018-12-19
EP19208066 2019-11-08

Publications (1)

Publication Number Publication Date
MA54503A true MA54503A (fr) 2021-10-27

Family

ID=68848313

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054503A MA54503A (fr) 2018-12-19 2019-12-18 Arn codant pour une protéine

Country Status (19)

Country Link
US (1) US20220002364A1 (fr)
EP (1) EP3898982A2 (fr)
JP (2) JP2022514863A (fr)
KR (1) KR20210105382A (fr)
CN (2) CN113454227B (fr)
AU (1) AU2019407921A1 (fr)
BR (1) BR112021011771A2 (fr)
CA (1) CA3120638A1 (fr)
CL (1) CL2021001571A1 (fr)
CO (1) CO2021007916A2 (fr)
IL (1) IL284035A (fr)
MA (1) MA54503A (fr)
MX (1) MX2021007241A (fr)
PE (1) PE20211342A1 (fr)
PH (1) PH12021551135A1 (fr)
SG (1) SG11202105267VA (fr)
TW (1) TW202043477A (fr)
WO (1) WO2020127532A2 (fr)
ZA (1) ZA202104912B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201466A1 (fr) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methodes de traitement de troubles metaboliques et de maladies cardiovasculaires avec des inhibiteurs de la sous-unite beta e de l'inhibine (inhbe)
CN117042723A (zh) * 2021-01-26 2023-11-10 西吉隆医疗股份有限公司 用于诱导抗原特异性免疫耐受的组合物、装置和方法
CN118076748A (zh) * 2021-03-01 2024-05-24 约翰·霍普金斯大学 通过自组装蛋白质进行分子索引(mipsa)以实现高效的蛋白质体学研究
WO2022216944A1 (fr) * 2021-04-07 2022-10-13 Mayo Foundation For Medical Education And Research Procédés et matériaux d'inversion de l'instabilité de la plaque d'athérome
EP4326312A1 (fr) * 2021-04-19 2024-02-28 Versameb AG Procédé de traitement de symptômes du tractus urinaire inférieur
EP4359533A2 (fr) * 2021-06-23 2024-05-01 Versameb AG Compositions et méthodes pour la modulation de l'expression de gènes
CN115992146B (zh) * 2022-11-11 2025-04-18 上海交通大学医学院附属第九人民医院 经修饰的mRNA分子及相关产品和用途
WO2024189146A1 (fr) * 2023-03-15 2024-09-19 Versameb Ag Arn codant pour une protéine
CN120400195B (zh) * 2024-05-14 2025-09-30 赛德特生物制药有限公司 一类改构的截短型il-24序列及其在治疗肿瘤中的应用
CN120209114B (zh) * 2025-03-07 2026-04-07 首都医科大学 一种含有penk蛋白的组合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69731660T2 (de) * 1996-12-02 2005-12-22 Valentis Inc., Burlingame Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung
ATE554784T1 (de) * 2001-05-25 2012-05-15 Cornell Res Foundation Inc Hochaffiner ligand für p75 neurotrophin-rezeptor
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
JP4451036B2 (ja) * 2001-11-30 2010-04-14 生化学工業株式会社 新規コンドロイチン合成酵素
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20090047259A1 (en) * 2005-12-22 2009-02-19 Enrique Lara Methods of Using the Calcineurin A Variant CnA-beta 1
EP2281047B1 (fr) * 2008-04-15 2020-04-08 Genzyme Corporation Procédés de production du facteur rdcvf
US20120093775A1 (en) * 2009-03-27 2012-04-19 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
CN102971002B (zh) * 2010-07-09 2019-04-05 国立大学法人东京大学 核酸递送用组合物及载体组合物、使用其的药物组合物以及核酸递送方法
ES2829199T3 (es) * 2010-11-22 2021-05-31 Amicus Therapeutics Inc Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas
CA2853379C (fr) * 2011-10-27 2020-11-24 Wellstat Ophthalmics Corporation Vecteurs codant pour un facteur de viabilite des cones derive des batonnets
US9994829B2 (en) * 2012-07-02 2018-06-12 Iprogen Biotech, Inc. Intracellular protein delivery
AU2015229035B2 (en) * 2014-03-14 2021-08-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
JP6581969B2 (ja) * 2014-04-24 2019-09-25 アキュルナ株式会社 タンパク質発現を向上させる方法およびタンパク質発現用組成物
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
GB201705484D0 (en) * 2017-04-05 2017-05-17 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
WO2020127532A3 (fr) 2020-09-17
SG11202105267VA (en) 2021-07-29
CN120519489A (zh) 2025-08-22
CA3120638A1 (fr) 2020-06-25
KR20210105382A (ko) 2021-08-26
CL2021001571A1 (es) 2022-04-18
AU2019407921A1 (en) 2021-06-10
EP3898982A2 (fr) 2021-10-27
US20220002364A1 (en) 2022-01-06
CN113454227A (zh) 2021-09-28
WO2020127532A2 (fr) 2020-06-25
IL284035A (en) 2021-08-31
TW202043477A (zh) 2020-12-01
JP2022514863A (ja) 2022-02-16
ZA202104912B (en) 2025-10-29
MX2021007241A (es) 2021-09-23
CO2021007916A2 (es) 2021-09-20
CN113454227B (zh) 2025-05-23
PH12021551135A1 (en) 2022-02-28
JP2024156665A (ja) 2024-11-06
PE20211342A1 (es) 2021-07-26
BR112021011771A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
MA54503A (fr) Arn codant pour une protéine
IL285152A (en) Predicting three-dimensional features for autonomous driving
EP3939251A4 (fr) Codage de contexte pour mode de saut de transformée
EP3610630A4 (fr) Interface logicielle pour contrats intelligents
EP4081547A4 (fr) Nouveaux anticorps anti-fgfr2b
EP3638789A4 (fr) Arn guides conditionnels
IL280400A (en) Nucleic acids encode enhanced transaminase proteins
EP3813234A4 (fr) Armature
EP4058710A4 (fr) Raccord renforcé
EP4081539A4 (fr) Nouveaux anticorps anti-fgfr2b
DK3840767T5 (da) Peptider
EP4048213A4 (fr) Injecteur intravitréen
PT3806660T (pt) Barra proteica
EP4037794C0 (fr) Bloc empilable
EP3644198C0 (fr) Conception 3d de peau b-rep
EP4041855C0 (fr) Adoucissant pour tissus
EP3918440A4 (fr) Manette inductive
EP4041854C0 (fr) Adoucissant pour tissus
EP3753553C0 (fr) Imprimante 3d
EP3882935A4 (fr) Transformateur pour véhicules
IL285757A (en) Three-dimensional nano-patterns
DK4025612T3 (da) Anti-fukosyl-gm1-antistoffer
EP4028507A4 (fr) Assembloïdes neuromodulateurs fonctionnels
EP3977441C0 (fr) Étui pour guitare
EP3761487A4 (fr) Armature